Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM.

Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.

2.

Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis.

Ashraf S, Bouhana KS, Pheneger J, Andrews SW, Walsh DA.

Arthritis Res Ther. 2016 May 4;18(1):97. doi: 10.1186/s13075-016-0996-z.

3.

Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers.

Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Bouhana KS, Trollinger D, Winkler J, Lee P, Andrews SW, Kuskowski MA, Mantyh PW.

Bone. 2011 Feb;48(2):389-98. doi: 10.1016/j.bone.2010.09.019. Epub 2010 Sep 18.

4.

Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens.

Parry TJ, Bouhana KS, Blanchard KS, Pavco PA, Sandberg JA.

Curr Issues Mol Biol. 2000 Oct;2(4):113-8.

5.

Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice.

Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L, Sandberg JA.

Hepatology. 2000 Sep;32(3):640-6.

PMID:
10960462
6.

Ribozymes as tools for therapeutic target validation in arthritis.

Jarvis TC, Bouhana KS, Lesch ME, Brown SA, Parry TJ, Schrier DJ, Hunt SW 3rd, Pavco PA, Flory CM.

J Immunol. 2000 Jul 1;165(1):493-8.

7.

Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.

Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ.

Clin Cancer Res. 2000 May;6(5):2094-103.

8.

Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse.

Sandberg JA, Bouhana KS, Gallegos AM, Agrawal AB, Grimm SL, Wincott FE, Reynolds MA, Pavco PA, Parry TJ.

Antisense Nucleic Acid Drug Dev. 1999 Jun;9(3):271-7.

PMID:
10435752
9.

Wound healing in the fetus. Possible role for inflammatory macrophages and transforming growth factor-beta isoforms.

Longaker MT, Bouhana KS, Harrison MR, Danielpour D, Roberts AB, Banda MJ.

Wound Repair Regen. 1994 Mar-Apr;2(2):104-12.

PMID:
17134379

Supplemental Content

Loading ...
Support Center